VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS

Clinical trial NCT06536959 · RECRUITING

Trial details

NCT number: NCT06536959
Sponsor: Beijing 302 Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Relapsed Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Myelodysplastic Syndromes Minimal Residual Disease

Start date: 2024-07-18
Primary completion: 2026-07-31
Enrollment: 67

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.